Strontium substituted bioactive glasses for tissue engineered scaffolds: the importance of octacalcium phosphate by unknown
BIOMATERIALS SYNTHESIS AND CHARACTERIZATION Original Research
Strontium substituted bioactive glasses for tissue engineered
scaffolds: the importance of octacalcium phosphate
Danujan Sriranganathan1 • Nasima Kanwal2 • Karin A. Hing3 • Robert G. Hill2
Received: 24 October 2015 /Accepted: 16 December 2015 / Published online: 24 December 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Porous bioactive glasses are attractive for use
as bone scaffolds. There is increasing interest in strontium
containing bone grafts, since strontium ions are known to
up-regulate osteoblasts and down regulate osteoclasts. This
paper investigates the influence of partial to full substitu-
tion of strontium for calcium on the dissolution and phase
formation of a multicomponent high phosphate content
bioactive glass. The glasses were synthesised by a high
temperature melt quench route and ground to a powder of
\38 microns. The dissolution of this powder and its ability
to form apatite like phases after immersion in Tris buffer
(pH 7.4) and simulated body fluid (SBF) was followed by
inductively coupled plasma optical emission spectroscopy
(ICP), Fourier transform infra red spectroscopy (FTIR),
X-ray powder diffraction (XRD) and 31P solid state nuclear
magnetic resonance spectroscopy up to 42 days of
immersion. ICP indicated that all three glasses dissolved at
approximately the same rate. The all calcium (SP-0Sr-
35Ca) glass showed evidence of apatite like phase forma-
tion in both Tris buffer and SBF, as demonstrated after
3 days by FTIR and XRD analysis of the precipitate that
formed during the acellular dissolution bioactivity studies.
The strontium substituted SP-17Sr-17Ca glass showed no
clear evidence of apatite like phase formation in Tris, but
evidence of an apatite like phase was observed after 7 days
incubation in SBF. The SP-35Sr-0Ca glass formed a new
crystalline phase termed ‘‘X Phase’’ in Tris buffer which
FTIR indicated was a form of crystalline orthophosphate.
The SP-35Sr-0Ca glass appeared to support apatite like
phase formation in SBF by 28 days incubation. The results
indicate that strontium substitution for calcium in high
phosphate content bioactive glasses can retard apatite like
phase formation. It is proposed that apatite formation with
high phosphate bioactive glasses occurs via an octacalcium
phosphate (OCP) precursor phase that subsequently trans-
forms to apatite. The equivalent octa-strontium phosphate
does not exist and consequently in the absence of calcium,
apatite formation does not occur. The amount of strontium
that can be substituted for calcium in OCP probably
determines the amount of strontium in the final apatite
phase and the speed with which it forms.
1 Introduction
A bone graft is a material that is surgically implanted into
an in vivo environment to aid the regeneration of bone
tissue to aid healing of a fracture or bone defect. Bone
grafts are designed to be surgically implanted into bone to
stimulate osteoregeneration and repair. There are many
different types of bone grafts, which are either harvested
naturally or produced synthetically [1]. The natural sources
of bone graft can be either allograft, xenograft or autograft
with the latter being considered the gold standard. How-
ever, each of these bone sources has disadvantages;
including disease transmission, rejection and limited sup-
ply which limits their use [2]. The issues particular to each
of these sources has been explored extensively in the
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literature [1–4]. Producing bone graft materials syntheti-
cally is regarded as a more reliable, reproducible, safer
method of supplying material for surgery, with the poten-
tial to be chemically and structurally optimised to match or
surpass the properties of bone grafts from natural sources.
An ideal bone graft will stimulate bone healing, while
being capable of undergoing controlled remodelling to
ultimately result in the formation of new bone in tandem
with the graft disappearing, as required. In addition, the
bone graft will initially provide structural stability so that
there is not any excessive stress or micromotion in the
vicinity of the defect site, which may slow bone healing.
The bone graft will also be biocompatible, cheap and easy
to use. For optimum bone healing there are three elements
which are essential. Osteogenic cells, such as osteoblasts
and osteoprogenitor cells in addition to phagocytic cells
such as macrophages and osteoclasts are required to ensure
that balanced new bone formation and bone remodelling
occurs. In addition, growth factors are needed to provide the
osteoinductive signals to activate the osteogenic cells [3].
The efficacy of a bone graft is measured by its level of
osteoinduction, osteoconduction and osseointegration [4].
Synthetically produced bone graft materials are termed
bone graft substitutes with one of the most actively studied
among surgeons and researchers being the bioactive glas-
ses. The original bioactive glass, Bioglass 45S5, was
invented in 1969 and still remains the gold standard in
bioactive glasses. The compositions of some of the most
widely studied bioactive glasses along with the glasses that
will be investigated in this paper are shown in Table 1.
For bioactive glasses to be effective as bone graft sub-
stitutes they must be sintered into porous scaffolds without
crystallisation occurring. They essentially act as a tempo-
rary template to guide the healing of the defect. They help
to stimulate vascularised bone growth and support bone
regeneration. The size of the sintering window is impor-
tant, with a large window allowing porous scaffolds to be
produced more easily. In addition to this there are a number
of other properties that a scaffold must have to be suc-
cessful [5].
A bone scaffold needs to be biocompatible in both its
original form and in its degradation products so that it does
not produce toxic by-products in vivo or activate the
immune system of the host, which will result in it being
rejected. The scaffold also needs to form a chemical bond
to the native bone as this will increase the structural sta-
bility of the defect site and is vital to its incorporation into
the function structure of the regenerated bone. In addition,
the mechanical properties of the scaffold need to be similar
to or lower than the native bone to ensure that the stress is
spread equally across both the scaffold and the native bone.
This is important as if this were not the case then over time
bone regeneration may be impaired or reversed. The sta-
bility of the structure is also influenced by the rate at which
the scaffold degrades which needs to be at the same rate at
which new bone is formed, and this is preferably cell
mediated through a natural remodelling process. The
physico-chemistry of the surface of the scaffold is also
important as it needs to facilitate osteogenic cell attach-
ment, as well as stimulating osteoprogenitor cells to pro-
duce a bone matrix [6–8].
One of the most important factors that determine the
success of a scaffold is its pores. The macropores need to
be open and interconnected so that angiogenesis can occur.
This is vital as the newly formed bone cannot survive
without a viable blood supply. However, if the macropores
are too large then the structural integrity of the scaffold
will be compromised. A number of studies have shown that
an interconnected pore structure is critical to the success of
a synthetic bone graft [9]. The macropore interconnections
of a scaffold with an osteoconductive chemistry need only
to be large enough to allow new bone growth and its
associated contiguous vascular network to penetrate freely
through the scaffold.
Bioglass 45S5 forms a carbonate-substituted hydrox-
yapatite layer on its surface in vivo which forms a strong
bond with the native tissues and bones. The new bone that
is formed will replace the Bioglass which degrades in the
body over time. The degradation time depends on the way
the Bioglass scaffold was sintered with various models
Table 1 Glass composition
(mol%) and network
connectivity (NC)
Glass 45S5 13–93 ICIE 16 Stronbone PTM
(SP-17Sr-17Ca)
SP-0Sr-35Ca SP-35Sr-0Ca
SiO2 46.13 54.6 49.46 44.5 44.5 44.5
P2O5 2.6 1.7 1.07 4.5 4.5 4.5
Na2O 24.35 6 6.6 4 4 4
K2O 0 7.9 6.6 4 4 4
CaO 26.91 22.1 36.27 17.8 35.6 0
SrO 0 0 0 17.8 0 35.6
MgO 0 7.7 0 7.5 7.5 7.5
NC 2.12 2.59 2.13 2.31 2.31 2.31
39 Page 2 of 10 J Mater Sci: Mater Med (2016) 27:39
123
being proposed in the literature to predict this with one
example being from a study by Sanz-Herrera and Boc-
caccini [10]. The degradation will also cause the release of
silicon ions as well as other ions such as calcium and
sodium [11]. However, the release of ions may not always
be a positive characteristic of Bioglass as in the early
stages of degradation there is a very fast release of ions,
which may cause changes in pH, which may disrupt the
homeostasis of the local environment [12]. Another limi-
tation of Bioglass is that there are difficulties in producing
porous scaffolds from it. The main reason for this is that
there is a small difference between its glass transition
temperature and its crystallisation temperature, the so
called processing or sintering window (defined as the onset
temperature for crystallisation minus the glass transition
temperature. These difficulties can lead to the formation of
a scaffold that has a low strength/cohesivity, [13]. Another
limitation is that Bioglass 45S5 has a slow degradation
rate and HA formation rate when compared to other
bioactive glasses, which makes it hard to predict the rate of
new tissue formation in vivo [14].
The 13–93 composition is based on Bioglass but dif-
fers in that it has a higher SiO2 content. Another distin-
guishing feature of the composition is the low phosphorus
content. Studies by O’Donnell, et al. [15] have shown that
with increasing phosphorus content there is faster apatite
formation and a smaller pH rise. This is advantageous as it
maintains the stability of the internal environment and
there is an increased bioactivity. Thus, the low PO4 content
of 13–93 could be considered disadvantageous. Another
disadvantage is that the 13–93 composition degrades at a
rate that is even slower than Bioglass 45S5. However, an
advantage that 13–93 has over Bioglass 45S5 is that it has
a much larger sintering window which means that porous
3D scaffolds can be created and sintered without crys-
tallisation occurring. This makes it easier to turn 13–93
into scaffolds for implantation in vivo [16]. The large
sintering window can be attributed to the presence of
magnesium oxide. A study conducted by Watts et al. [17]
showed that magnesium oxide extends the sintering win-
dow by inhibiting crystallisation but the side effect is that it
limits bioactivity by reducing apatite formation. Thus, in
formulating the 13–93 glass a compromise was made
between its level of bioactivity and its ability to be made
into a scaffold.
ICIE 16 is a bioactive glass composition that was
designed by Wu et al. [18] primarily not to crystallise
during sintering, while having similar bioactivity to the
45S5 composition. This eliminates one of the major dis-
advantages of Bioglass. Analysis of the ICIE16 compo-
sition found that the sintering window was[200 C, which
is more than double that of the 45S5 composition, which is
just below 100 C. It was also found that apatite formation
in ICIE16 was accelerated as compared to that of the 13–93
composition, matching the rates observed for 45S5. The
explanation proposed for this behaviour was that ICIE16
had a similar network connectivity to 45S5, which is lower
than that of 13–93. Network connectivity (NC) is important
as higher values result in slower ion exchange and disso-
lution, which are important steps in the apatite formation
mechanism. The NC for the different glass compositions
are given in Table 1 [18].
In recent years the positive effects of strontium on bone
metabolism have become widely recognised. Strontium
ions have been found to inhibit osteoclast activity, while
promoting osteoblast activity, which facilitates bone for-
mation. Strontium has also been found to have a mild
bactericidal effect at the same concentration that it up
regulates osteoblast activity, which is a very advantageous
property [19, 20]. However, too much strontium can have
negative effects. The inhibition of too many osteoclast cells
will inhibit bone regeneration and bone remodelling. The
lack of remodelling and regeneration can lead to
osteonecrosis and can cause the bones to become brittle.
Thus, it is important to ensure an optimal level of strontium
in the candidate glass composition [21]. Analysis of
strontium ions show that it is very similar, chemically, to
calcium, as they are both in group II of the periodic table,
resulting in similar electrochemical properties. They are
also somewhat similar in size with strontium ions having
an ionic radius of 1.16 A˚ and calcium ions having a radius
of 0.94 A˚. Due to the similarities with calcium and the
desirable properties that strontium possesses, it was
hypothesised that strontium oxide (SrO) could be substi-
tuted for calcium oxide (CaO) in Bioglass to combine the
positive properties of both Bioglass and strontium [22].
A series of strontium containing bioactive glasses were
patented by Hill and Stevens [23] and one of these com-
positions was then subsequently turned into a commercial
product called StronboneTM by RepRegen Ltd, UK.
Stronbone-PTM is a variant of the original StronboneTM
with the ‘‘P’’ in its name indicating the fact that it is a more
porous version. In order to make a porous version and to
enable sintering the chemical composition of the glass had
to be modified to increase the size of the processing or
sintering window to 174 C, which makes it ideal for
forming scaffolds and sintering. Preliminary testing has
shown that Stronbone-PTM has a more rapid bone growth
and remodelling rate than the original StronboneTM.
In this paper the findings of in vitro studies carried out to
assess the ‘bioactivity’ in terms of the acellular dissolution
and reprecipitation behaviour of Stronbone-PTM will be
reported. The powder version of bioactive glasses were
used instead of the sintered scaffold version so that the
dissolution and reprecipitation rate of the glass alone could
be evaluated. It is a commonly reported finding that
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forming an scaffold can affect this rate [12]. This is clin-
ically relevant as the powder form can have dental appli-
cations such as in toothpaste formulations. Stronbone-PTM
was analysed in both simulated body fluid (SBF) and Tris
buffer solution for various time points up to 42 days. The
decision was also taken to produce two variants of Stron-
bone-PTM, in order to directly assess the effect of the
presence of calcium and/or strontium on apatite forming
ability. An all strontium version where the calcium is
completely replaced with strontium to produce a strontium
only Stronbone PTM glass, was called the SP-35Sr0Ca. The
second variant had the strontium replaced with calcium to
produce a calcium only Stronbone PTM, was called the SP-
0Sr35Ca. To aid clarity, for the remainder of this paper
Stronbone-PTM shall be referred to as the SP-17Sr17Ca to
maintain uniformity with the other two variants that are
named according to the relative percentage of strontium
they contain.
2 Materials and methods
The three glass compositions studied are given in Table 1.
Proportions of the relevant oxides were mixed together in a
platinum crucible and heated to 1460 C for SP-17Sr17Ca,
1450 C for SP-0Sr35Ca or 1470 C for SP-35Sr0Ca. The
different temperatures used reflected the effect that stron-
tium has on the melting temperature. Once the furnace was
at the desired temperature the glass was held for 1 h and
then quenched using deionised water. The coarse granular
frit glass was collected, dried overnight and ground into
powder using a Gy-Ro Mill (Glen Creston Ltd, Twicken-
ham UK) and sieved using an Endecotts EFL 2000/1
automated sieve shaker to separate the powder into a fine
(\38 lm) and coarse frit. The fine and coarse frit were then
analysed using differential scanning calorimetry (DSC) to
determine the glass transition temperature (Tg) crystalli-
sation onset temperature (Tconset) and processing window
(defined as Tconset-Tg).
The acellular ‘bioactivity’ dissolution/reprecipitation
tests were conducted at 37 C in a rollerball incubator with
a rotational speed of 60 rpm, using 150 mg fine frit glass
incubated for periods of 1, 3, 7, 14, 28 and 42 days in
100 mL of either Tris buffer solution or simulated body
fluid (SBF) [24]. After the various time intervals had pas-
sed the solution was filtered and refrigerated prior to
analysis. Inductively coupled plasma optical emission
spectroscopy (ICP-OES) was carried out to monitor ion
release at different time points. The solid precipitate
formed on the bioglass frit during the bioactivity tests was
collected during the solution filtration step along with any
remaining frit, dried in an oven at 37 C for 24 h and
together analysed for glass degradation and apatite for-
mation using Fourier transform infrared (FTIR) and X-ray
diffraction (XRD) as previously described [25], in addition
to 31P magic angle spinning nuclear magnetic resonance
(MAS-NMR).
31P MAS NMR spectra were acquired on a Bruker
Avance 600 spectrometer at the Larmor frequency of
242.96 MHz. All spectra were acquired with a single 90o
pulse. Samples were packed into 4 mm outer diameter
Zirconia rotors and spun at the magic angle at a spinning
speed of 12 kHz. Each spectrum is a sum of 16 scans
acquired with a 60 s recycle delay. Spectra were externally






































Fig. 2 DSC trace of fine powder (uppermost line) and coarse frit
(lowermost line) of the SP-17Sr17Ca
Table 2 Glass transition and crystallisation onset temperatures for
the glasses
Glass Tg (C) Tg-Tcons (C) Tc (C)
SP-35Sr-0Ca 578 260 874
SP-17Sr-17Ca 614 193 879
SP-0Sr-35Ca 618 247 907
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3 Results and discussion
The XRD trace in Fig. 1 shows that all the glass compo-
sitions under investigation were amorphous, with the
presence of a broad amorphous peak as is typical of
bioactive glasses. It was also evident that the amorphous
peak had a higher intensity and was shifted more to lower
2h values with increasing strontium content. The intensity
variation could be attributed to the fact that strontium has a
higher atomic number than calcium and thus scatters
X-rays more effectively. While the shift towards lower 2h
values could be explained by considering the Braggs
diffraction equation. The equation is gc = 2dsinh with
‘‘gc’’ being a fixed value and ‘‘d’’ being the space between
the atoms of the glass. As strontium is a larger atom than
calcium, the spacings in the glass are larger and thus the
sinh value is smaller, which shifts the maximum in the
amorphous scattering to lower 2h values [26, 27].
The fine powder and coarse frit have very similar glass
transition temperatures (Tg) and large sintering windows as
is evident in Fig. 2. The processing windows is larger for the
coarse frit which implies that crystallization occurs by sur-
face nucleation, as the coarser frit glass will have lower
surface area to volume ratio than the fine frit glass. The large
reduction in heat flux following the Tg with fine powder
which is absent with coarse frit is a result of the sintering and
compaction of the glass and is indicative of the ease of vis-
cous flow sintering that occurs with these glasses.
The results of the DSC analysis show that Tg decreases
with increasing strontium content, which is evident in
Table 2 and can be explained by the fact that the strontium
ion is larger than the calcium ion and results in a less dense
glass network [26]. The size of the sintering window is also
affected by the presence of strontium with a high level of
strontium increasing the sintering window.
There is clear evidence of the formation of an apatite
like phase with the SP-0Sr35Ca in Tris buffer solution and
SBF when analysed with FTIR and XRD. Figure 3a, c
show the appearance of peaks at 26 and 32 from 3 days,
which is indicative of apatite formation. This is supported
by the split bands at 560, and 600 cm-1 from 3 days in the
FTIR spectra Fig. 3b and split bands at 570, 612 and
1420 cm-1 which are also indicative of the presence of an
apatite like phase. In Fig. 3b, d, the changes in the FTIR
traces over time shows the loss of non-bridging oxygen and
the development of a phosphate peak behaviour that is
expected of the glass. The development of the phosphate




























































































Fig. 3 a XRD of SP-0Sr35Ca in Tris buffer solution, b FTIR of SP-0Sr35Ca in Tris buffer solution, c XRD of SP-0Sr35Ca in SBF and d FTIR
of SP-0Sr35Ca in SBF
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The SP-17Sr17Ca shows a marked difference in the
XRD results after immersion in SBF and Tris. On incu-
bation in SBF (Fig. 4c) there are clear signs of develop-
ment of an apatite like phase as two peaks appear at 26
and 32 from 14 days. However, on incubation of the Tris
buffer (Fig. 4a) there seems to be the growth of a broad
peak centred around 32 which corresponds to three of the
principle diffraction lines of apatite but it isn’t very clear.
The lack of evidence of the presence of an apatite like
phase can be attributed to the lack of calcium in Tris that
could be preventing or delaying apatite formation. The
FTIR results supports the findings of the XRD with there
being signs of apatite formation on incubation in the SBF
(Fig. 4d) as split bands are present around 560 and
600 cm-1 from 7 days. However, after incubation in the
Tris (Fig. 4b) there are only signs of the formation of the
split bands from 28 days and the splitting is not very
obvious. This is consistent with the XRD results where the
diffraction lines for apatite are not very clear.
The SP-35Sr0Ca behaved differently to both the 0 %
and SP-17Sr17Caes. Analysis by XRD (Fig. 5a) of SP-
35Sr0Ca exposed to Tris buffer solution demonstrated the
appearance of a new highly crystalline phase that cannot be
matched to common strontium and/or phosphate based
compounds. This new phase appeared after 7 days and is
termed ‘‘X phase’’. X phase did not match Collin’s salt
[Sr6H3(PO4)52H2O], tristrontium phosphate or strontium
apatite. It is hypothesised that it is most likely to be some
form of strontium orthophosphate as it shares diffraction
lines with Collin’s salt [28]. This hypothesis is supported
by the FTIR (Fig. 5b) which exhibits split bands at 555,
597 and a band at 1100 cm-1 which indicate that there is
some type of orthophosphate present [29]. The analysis of
the SP-35Sr0Ca in SBF shows no clear signs of apatite
formation. In the XRD (Fig. 5c) there is a growth in the
region of 30–33, at all time points, which is where an
apatite phase would be found. FTIR analysis demonstrated
the growth of a broad peak at around 1100 cm-1 and split
bands around 560 and 600 cm-1, which could be evidence
of the early evolution of an apatite like phase, but it is not
very clear.
The spectra remain fairly broad even after immersion for
28 days both in Tris buffer and SBF, except for SP-






























































































Fig. 4 a XRD of SP-17Sr17Ca in Tris buffer solution, b FTIR of SP-17Sr17Ca in Tris buffer solution, c XRD of SP-17Sr17Ca in SBF and
d FTIR of SP-17Sr17Ca in SBF
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position compared to untreated glass. Chemical shift goes
down to about 3 ppm which is an indication of apatite like
phase formation [30]. Analysis of SP-0Sr35Ca after
28 days immersion (Fig. 6a, b, iii) shows a much sharper
peak with chemical shift of 2.8 ppm which is a clear
indication of apatite formation. In agreement with XRD
and FTIR results, the SP-35Sr0Ca shows unexpected
results with a very low chemical shift of 0.5 ppm in Tris
buffer (Fig. 6b, iv–vi) which is an indication of some
acidic orthophosphate formation, however in SBF (Fig. 6b,
iv–vi) spectral peaks are broad and fairly symmetric with
chemical shift centred at about 3 ppm.
The ICP analysis is consistent with the XRD and FTIR
with phosphorus and calcium levels reducing as expected
when an apatite like phase was being produced. The sil-
icon release is very similar for all the glasses in both
immersion media. This can be clearly seen in Fig. 7
where there is an increase in silicon as the glasses dis-
solve and then there is a plateau at around 60 mg/L. In all
of the glasses, in the first 5 days there is a rapid release of
silicon which then slows to reach a plateau at 7 days.
This level of silicon release is not concerning as there are
no reported symptoms or toxic effects on the human body
in the literature and although its exact role in the body
has not been fully ascertained, it does play a role in
collagen synthesis and bone matrix development [31].
Another assumption that can be made is that as the dis-
solution rate of the glasses are not significantly different,
the apatite like phase formation must be attributed to the
glass compositions themselves and not as a result of the
glasses dissolving at different rates. This is supported by
all the XRD data where there is a consistent growth in all
the glasses at around 23 2h, which signifies the growth
of an amorphous peak that is thought to correspond to
silica gel. This occurs simultaneously with the loss of
scattering around 28 as the glass dissolves. Another
feature of the XRD data that is consistent is that glasses
immersed in SBF have broader peaks than the glasses
immersed in Tris. This can be attributed to the presence
of magnesium ions in the SBF that reduces the apatite
crystallite size and causes Scherrerr line broadening.
Scherrerr line broadening also explains why the peaks
sharpen at the later time points in the XRD data, corre-
































































































Fig. 5 a XRD of SP-35Sr0Ca in Tris buffer solution, b FTIR of SP-35Sr0Ca in Tris buffer solution, c XRD of SP-35Sr0Ca in SBF and d FTIR
of SP-35Sr0Ca in SBF
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Octacalcium phosphate, Ca8(PO4)6H25H2O (OCP) is
thought to be a precursor to apatite formation with evi-
dence of OCP formation found in the natural mineralisation
processes of enamel and bone [33–36]. Whilst hydroxya-
patite is the thermodynamically most stable phase, OCP is
thought to form because it has a lower activation energy of
nucleation, as a result of the water layer in its structure
reducing the interfacial surface energy upon nucleation in
water. OCP has a crystal structure very similar to
hydroxyapatite, and X-ray diffraction patterns for OCP and
hydroxyapatite are almost indistinguishable [34]. The only
major difference being a diffraction peak at 4.6 2h (with
CuKa X-rays), corresponding to the water layer which is in
OCP, but not HA. This diffraction peak is problematic to
detect since it is (i) at a very small angle, (ii) tends to
broaden out as a result of any structural disorder and (iii)
OCP tends to form as very thin plates in this crystallo-
graphic direction resulting in chronic Scherrer line broad-
ening [33–36]. To make detection of OCP even more
problematic OCP is not thermodynamically stable and
drying it or putting it under vacuum favours the loss of
water and conversion to an apatite. It is worth considering
that OCP and hydroxyapatite are two extreme members in
a spectrum of calcium phosphates whose exact chemical
composition probably depends on the pH conditions and
degree of supersaturation (33, 35). The formation of OCP
is generally favoured by less basic pHs and higher P:Ca
ratios [35].
OCP is thought to form in the SP-0Sr35Ca and the SP-









Fig. 6 a 31P NMR spectra of
unimmersed coarse powder, fine
frit after 3 days immersion and
fine frit after 28 days immersion
for SP-0Sr35Ca (i, ii, iii), SP-
17Sr17Ca (iv, v, vi) and SP-
35Sr0Ca (vii, viii, ix) in Tris
buffer solution. b 31P NMR
spectra of unimmersed coarse
powder, fine frit after 3 days
immersion and fine frit after
28 days immersion for SP-
0Sr35Ca (i, ii, iii), SP-17Sr17Ca
(iv, v, vi) and SP-35Sr0Ca (vii,























Fig. 7 Silicon ion release in Tris buffer solution for the SP-0Sr-35Ca,
SP-17Sr-17Ca and SP-35Sr-0Ca formulations over the 42 day period
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be substituted into the OCP crystal lattice without desta-
bilising it. However, large amounts of strontium are unli-
kely to be substituted into the lattice as there is not a
recognised stable form of octa strontium phosphate. At
above a certain degree of strontium substitution for calcium
in OCP, the OCP becomes unstable. This extreme scenario
occurs with the SP-35Sr0Ca in Tris buffer, since there is no
source of calcium, OCP cannot form and instead a new
crystalline strontium orthophosphate forms. While in SBF
apatite formation is inhibited in the presence of the SP-
35Sr0Ca, supporting the theory that OCP is a precursor to
apatite formation, as calcium is only available from the
SBF and the OCP structure is unable to accommodate too
great a level of strontium into its lattice without becoming
destabilised. This is reflected in results of this paper where
the most clear evidence of apatite like phase formation is
seen in with the SP-0Sr35Ca, where there are no strontium
ions. The apatite like phase formation is less obvious with
the SP-17Sr17Ca and it appears as if there is no apatite
formation with the SP-35Sr0Ca in Tris. Previous studies
conducted by this research group have shown that with
increasing strontium concentration the rate of apatite for-
mation increases. A possible explanation for these appar-
ently contradictory results could be that the previous
studies were all performed with glasses containing fluoride
or low levels of phosphate. Fluoride is thought to eliminate
the requirement for an OCP precursor phase during apatite
formation [37]. Thus, it might be the case that strontium
will only have a positive effect on apatite formation in high
phosphate content bioactive glasses when fluorine is also
present. However, further studies with fluorine substituted
glasses of the compositions used in this paper are required
in order to test this hypothesis. A previous study by
Gentleman et al. [38], investigating strontium incorpora-
tion into bioactive glasses used low phosphate contents of
1.07 and 2.6 mol% P2O5 compared to the higher level of
4.5 mol% used in the glasses of the present study. The low
phosphate content coupled with the much higher pH rise
with these glasses and the fact these studies were carried
out in SBF is likely to favour the direct formation of a
hydroxycarbonated like apatite, rather than going via a
precursor OCP route. At high pH[ 9 direct formation of a
hydroxyapatite is thought to occur and under these condi-
tions strontium exhibits complete solid substitution for
calcium in the hydroxyapatite lattice [26].
4 Conclusion
The results indicate that increasing the substitution of
calcium for strontium in high phosphate bioactive glasses
appears to retard the formation of an apatite like phase. It is
proposed that apatite formation proceeds via the formation
of an octacalcium phosphate precursor phase, which then
transforms towards a hydroxycarbonated apatite. Above a
certain concentration of Sr or Sr/Ca ratio, the Octacalcium
phosphate precursor phase is unable to form which ulti-
mately retards the formation of a hydroxycarbonate like
phase. The complete absence of calcium in the SP-35Sr-
0Ca glass in Tris buffer results in a completely new
orthophosphate phase, which could not be identified. Fur-
ther experiments are required to determine the structure of
this new phase as it may provide further clues into
understanding the role of Sr on bone formation. Identifying
the optimum level of strontium substitution is also impor-
tant as it will allow the formulation of Stronbone PTM to be
improved.
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commons.org/licenses/by/4.0/), which permits unrestricted use,
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to the Creative Commons license, and indicate if changes were made.
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